image
Healthcare - Biotechnology - NASDAQ - US
$ 4.46
-1.9 %
$ 249 M
Market Cap
-3.19
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one FHTX stock under the worst case scenario is HIDDEN Compared to the current market price of 4.46 USD, Foghorn Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one FHTX stock under the base case scenario is HIDDEN Compared to the current market price of 4.46 USD, Foghorn Therapeutics Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one FHTX stock under the best case scenario is HIDDEN Compared to the current market price of 4.46 USD, Foghorn Therapeutics Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart FHTX

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
22.6 M REVENUE
-33.83%
-103 M OPERATING INCOME
4.84%
-86.6 M NET INCOME
11.99%
-100 M OPERATING CASH FLOW
14.99%
-29.9 M INVESTING CASH FLOW
-20.70%
105 M FINANCING CASH FLOW
5829.58%
5.95 M REVENUE
108.40%
-22.9 M OPERATING INCOME
4.55%
-18.8 M NET INCOME
3.43%
-24 M OPERATING CASH FLOW
2.25%
29.4 M INVESTING CASH FLOW
31.90%
139 K FINANCING CASH FLOW
3375.00%
Balance Sheet Foghorn Therapeutics Inc.
image
Current Assets 250 M
Cash & Short-Term Investments 244 M
Receivables 0
Other Current Assets 5.85 M
Non-Current Assets 34.4 M
Long-Term Investments 0
PP&E 32.6 M
Other Non-Current Assets 1.78 M
85.83 %11.48 %Total Assets$284.0m
Current Liabilities 67 M
Accounts Payable 3.78 M
Short-Term Debt 18.1 M
Other Current Liabilities 45.1 M
Non-Current Liabilities 263 M
Long-Term Debt 56.1 M
Other Non-Current Liabilities 206 M
5.50 %13.68 %17.03 %62.64 %Total Liabilities$329.5m
EFFICIENCY
Earnings Waterfall Foghorn Therapeutics Inc.
image
Revenue 22.6 M
Cost Of Revenue 0
Gross Profit 22.6 M
Operating Expenses 125 M
Operating Income -103 M
Other Expenses -16.1 M
Net Income -86.6 M
40m40m20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)23m023m(125m)(103m)16m(87m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-454.31% OPERATING MARGIN
-454.31%
-383.24% NET MARGIN
-383.24%
190.26% ROE
190.26%
-30.50% ROA
-30.50%
-43.67% ROIC
-43.67%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Foghorn Therapeutics Inc.
image
200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)(150m)(150m)20192019202020202021202120222022202320232024202420252025
Net Income -86.6 M
Depreciation & Amortization 3.12 M
Capital Expenditures -906 K
Stock-Based Compensation 11.9 M
Change in Working Capital -32.3 M
Others -26.3 M
Free Cash Flow -101 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Foghorn Therapeutics Inc.
image
Wall Street analysts predict an average 1-year price target for FHTX of $14 , with forecasts ranging from a low of $9 to a high of $20 .
FHTX Lowest Price Target Wall Street Target
9 USD 101.79%
FHTX Average Price Target Wall Street Target
14 USD 213.90%
FHTX Highest Price Target Wall Street Target
20 USD 348.43%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088664422Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Foghorn Therapeutics Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
591 K USD 1
9-12 MONTHS
190 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in Evercore Biotech Diamonds in the Rough Virtual Event, TD Cowen's 6th Annual Oncology Innovation Summit, Jefferies Global Healthcare Conference 2025 and Goldman Sachs 46th Annual Global Healthcare Conference 2025. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. globenewswire.com - 3 weeks ago
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago. zacks.com - 1 month ago
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026 Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of  $220.6 million as of March 31, 2025 , provides cash runway into 2027 CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company's 10-Q filing for the quarter ended March 31, 2025. globenewswire.com - 1 month ago
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Citizens Life Sciences Conference, being held May 7-8, 2025, in New York, NY. globenewswire.com - 1 month ago
Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. globenewswire.com - 1 month ago
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population globenewswire.com - 1 month ago
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population globenewswire.com - 2 months ago
Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting - FHD-909 (LY4050784) advancing in an ongoing Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population globenewswire.com - 2 months ago
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.57 per share a year ago. zacks.com - 3 months ago
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population globenewswire.com - 3 months ago
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 months ago
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the B. Riley Securities Precision Oncology and Radiopharma Conference, and at the TD Cowen 45th Annual Health Care Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. globenewswire.com - 3 months ago
8. Profile Summary

Foghorn Therapeutics Inc. FHTX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 249 M
Dividend Yield 0.00%
Description Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Contact 500 Technology Square, Cambridge, MA, 02139 https://foghorntx.com
IPO Date Oct. 23, 2020
Employees 112
Officers Dr. Gerald R. Crabtree M.d. Founder & Member of Scientific Advisory Board Mr. Kristian Humer M.B.A. Chief Financial Officer Mr. Michael J. LaCascia J.D. Chief Legal Officer Dr. Steven F. Bellon Ph.D. Chief Scientific Officer Mr. Adrian H. B. Gottschalk President, Chief Executive Officer & Director Ms. Karin Hellsvik Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs & Investor Relations Mr. Carlos Costa Chief People Officer Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer Dr. Anna Rivkin Ph.D. Chief Business Officer Mr. Saurabh Sewak Ph.D. Vice President of Corporate Development